Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Bayer Consumer Care AG
Sponsor

Bayer Consumer Care AG

Peter Merian-Strasse 84, 4052

About the sponsor

Clinical research includes metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, biochemically recurrent prostate cancer, and broader advanced solid tumors. The portfolio also covers PSMA-expressing disease and hepatocellular carcinoma, with interest in tumor control and disease progression across advanced oncology settings.

  • PSMA-targeted prostate cancer
  • metastatic hormone-sensitive prostate cancer
  • hepatocellular carcinoma
  • advanced solid tumors

Additional activity extends to radionuclide therapy and androgen deprivation therapy in prostate cancer, reflecting sustained involvement in treatment areas linked to advanced genitourinary malignancies.

About Specializations

Bayer Consumer Care AG runs clinical trials in conditions such as Neoplasm malignant, Menopausal symptoms, Testosterone deficiency syndrome, Hot flush, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

14 clinical trials

Cardiac amyloidosis

Recruiting

A Study of Acoramidis in Adult Patients with Transthyretin Amyloidosis with Cardiomyopathy Who Previously Received Tafamidis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Bayer Consumer Care AG

Endometrial cancer+18

Recruiting

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:BAY 2927088
  • Sponsor:Bayer AG

Testosterone deficiency syndrome+2

Not recruiting

Bioavailability, Safety and Tolerability of elinzanetant (BAY 3427080) in Healthy Adults for Treatment of Vasomotor Symptoms

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Testosterone deficiency syndrome+2

Not recruiting

Relative bioavailability and safety of elinzanetant soft‑gel capsules in healthy adults for vasomotor symptoms

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Testosterone deficiency syndrome+1

Not recruiting

Study on How Elinzanetant Affects Dabigatran Etexilate in Healthy Volunteers with Vasomotor Symptoms

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Dabigatran Etexilate
  • Sponsor:Bayer AG

Hormone-refractory prostate cancer

Not recruiting

Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Bayer AG

Autonomic nervous system imbalance+1

Not recruiting

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Sleep disorder+1

Not recruiting

Study on Elinzanetant for Treating Sleep Disturbances in Menopausal Women

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Factor VIII deficiency

Not recruiting

Safety Study of Damoctocog Alfa Pegol for Children Aged 7 to 11 with Severe Hemophilia A

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Damoctocog Alfa Pegol
  • Sponsor:Bayer AG

Neoplasm malignant+2

Not recruiting

Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

Neoplasm malignant+1

Not recruiting

Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

Prostate cancer metastatic

Not recruiting

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.